» Articles » PMID: 35954312

Vitamin D, Th17 Lymphocytes, and Breast Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Aug 12
PMID 35954312
Authors
Affiliations
Soon will be listed here.
Abstract

Vitamin D, which is well known to maintain calcium homeostasis, plays an important role in various cellular processes. It regulates the proliferation and differentiation of several normal cells, including immune and neoplastic cells, influences the cell cycle, and stimulates cell maturation and apoptosis through a mechanism dependent on the vitamin D receptor. The involvement of vitamin D in breast cancer development has been observed in numerous clinical studies. However, not all studies support the protective effect of vitamin D against the development of this condition. Furthermore, animal studies have revealed that calcitriol or its analogs may stimulate tumor growth or metastasis in some breast cancer models. It has been postulated that the effect of vitamin D on T helper (Th) 17 lymphocytes is one of the mechanisms promoting metastasis in these murine models. Herein we present a literature review on the existing data according to the interplay between vitamin D, Th17 cell and breast cancer. We also discuss the effects of this vitamin on Th17 lymphocytes in various disease entities known to date, due to the scarcity of scientific data on Th17 lymphocytes and breast cancer. The presented data indicate that the effect of vitamin D on breast cancer development depends on many factors, such as age, menopausal status, or obesity. According to that, more extensive clinical trials and studies are needed to assess the importance of vitamin D in breast cancer, especially when no correlations seem to be obvious.

Citing Articles

Vitamin D receptor is associated with prognostic characteristics of breast cancer after neoadjuvant chemotherapy-an observational study.

Streb J, Lazarczyk A, Halubiec P, Streb-Smolen A, Ciurus J, Ulatowska-Bialas M Front Oncol. 2024; 14:1458124.

PMID: 39411136 PMC: 11476186. DOI: 10.3389/fonc.2024.1458124.


Vitamin D reduces the expression of M1 and M2 macrophage markers in breast cancer patients.

Stachowicz-Suhs M, Labedz N, Milczarek M, Klopotowska D, Filip-Psurska B, Maciejczyk A Sci Rep. 2024; 14(1):22126.

PMID: 39333342 PMC: 11437092. DOI: 10.1038/s41598-024-73152-x.


Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer.

Ma S, Hao R, Lu Y, Wang H, Hu J, Qi Y Breast Cancer (Dove Med Press). 2024; 16:199-219.

PMID: 38634039 PMC: 11021863. DOI: 10.2147/BCTT.S448642.


Calcitriol promotes M2 polarization of tumor-associated macrophages in 4T1 mouse mammary gland cancer via the induction of proinflammatory cytokines.

Stachowicz-Suhs M, Labedz N, Anisiewicz A, Banach J, Klopotowska D, Milczarek M Sci Rep. 2024; 14(1):3778.

PMID: 38355711 PMC: 10866890. DOI: 10.1038/s41598-024-54433-x.


Vitamin D and potential effects on cancers: a review.

Sobhi P, Bahrami M, Mahdizadeh F, Fazaeli A, Babaei G, Rezagholizadeh L Mol Biol Rep. 2024; 51(1):190.

PMID: 38270702 DOI: 10.1007/s11033-023-09111-y.


References
1.
Swami S, Krishnan A, Williams J, Aggarwal A, Albertelli M, Horst R . Vitamin D mitigates the adverse effects of obesity on breast cancer in mice. Endocr Relat Cancer. 2016; 23(4):251-64. PMC: 4889430. DOI: 10.1530/ERC-15-0557. View

2.
Baaten B, Li C, Bradley L . Multifaceted regulation of T cells by CD44. Commun Integr Biol. 2011; 3(6):508-12. PMC: 3038050. DOI: 10.4161/cib.3.6.13495. View

3.
Palmieri C, MacGregor T, Girgis S, Vigushin D . Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol. 2006; 59(12):1334-6. PMC: 1860540. DOI: 10.1136/jcp.2006.042747. View

4.
Huang C, Hydo L, Liu S, Miller R . Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells. Cell Signal. 2009; 21(12):1894-900. DOI: 10.1016/j.cellsig.2009.08.004. View

5.
Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese L . Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010; 10:483. PMC: 2945944. DOI: 10.1186/1471-2407-10-483. View